271 related articles for article (PubMed ID: 33653799)
1. Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity.
Gao A; Liu X; Lin W; Wang J; Wang S; Si F; Huang L; Zhao Y; Sun Y; Peng G
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33653799
[TBL] [Abstract][Full Text] [Related]
2. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
3. ILT4 functions as a potential checkpoint molecule for tumor immunotherapy.
Gao A; Sun Y; Peng G
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):278-285. PubMed ID: 29649510
[TBL] [Abstract][Full Text] [Related]
4. Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy.
Liu X; Si F; Bagley D; Ma F; Zhang Y; Tao Y; Shaw E; Peng G
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192086
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory receptor immunoglobulin-like transcript 4 was highly expressed in primary ductal and lobular breast cancer and significantly correlated with IL-10.
Liu J; Wang L; Gao W; Li L; Cui X; Yang H; Lin W; Dang Q; Zhang N; Sun Y
Diagn Pathol; 2014 Apr; 9():85. PubMed ID: 24762057
[TBL] [Abstract][Full Text] [Related]
6. TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence.
Ye J; Ma C; Hsueh EC; Dou J; Mo W; Liu S; Han B; Huang Y; Zhang Y; Varvares MA; Hoft DF; Peng G
EMBO Mol Med; 2014 Oct; 6(10):1294-311. PubMed ID: 25231413
[TBL] [Abstract][Full Text] [Related]
7. ILT2 and ILT4 Drive Myeloid Suppression via Both Overlapping and Distinct Mechanisms.
Tian J; Ashique AM; Weeks S; Lan T; Yang H; Chen HH; Song C; Koyano K; Mondal K; Tsai D; Cheung I; Moshrefi M; Kekatpure A; Fan B; Li B; Qurashi S; Rocha L; Aguayo J; Rodgers C; Meza M; Heeke D; Medfisch SM; Chu C; Starck S; Basak NP; Sankaran S; Malhotra M; Crawley S; Tran TT; Duey DY; Ho C; Mikaelian I; Liu W; Rivera LB; Huang J; Paavola KJ; O'Hollaren K; Blum LK; Lin VY; Chen P; Iyer A; He S; Roda JM; Wang Y; Sissons J; Kutach AK; Kaplan DD; Stone GW
Cancer Immunol Res; 2024 May; 12(5):592-613. PubMed ID: 38393969
[TBL] [Abstract][Full Text] [Related]
8. ILT4 in Colorectal Cancer Cells Induces Suppressive T Cell Contexture and Disease Progression.
Yang Z; Gao A; Shi W; Wang J; Zhang X; Xu Z; Xu T; Zheng Y; Sun Y; Yang F
Onco Targets Ther; 2021; 14():4239-4254. PubMed ID: 34321889
[TBL] [Abstract][Full Text] [Related]
9. ILT4 facilitates angiogenesis in non-small cell lung cancer.
Wang S; Wang J; Gong W; Zhang F; Chen X; Xu H; Han Y; Fu X; Wang L; Li J; Gao A; Sun Y
Cancer Sci; 2024 May; 115(5):1459-1475. PubMed ID: 38433526
[TBL] [Abstract][Full Text] [Related]
10. ILT4 drives B7-H3 expression via PI3K/AKT/mTOR signalling and ILT4/B7-H3 co-expression correlates with poor prognosis in non-small cell lung cancer.
Zhang P; Yu S; Li H; Liu C; Li J; Lin W; Gao A; Wang L; Gao W; Sun Y
FEBS Lett; 2015 Aug; 589(17):2248-56. PubMed ID: 26149216
[TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin-like transcript 4 promotes tumor progression and metastasis and up-regulates VEGF-C expression via ERK signaling pathway in non-small cell lung cancer.
Zhang P; Guo X; Li J; Yu S; Wang L; Jiang G; Yang D; Wei Z; Zhang N; Liu J; Sun Y
Oncotarget; 2015 May; 6(15):13550-63. PubMed ID: 25948790
[TBL] [Abstract][Full Text] [Related]
12. DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells.
Cueto FJ; Del Fresno C; Brandi P; Combes AJ; Hernández-García E; Sánchez-Paulete AR; Enamorado M; Bromley CP; Gomez MJ; Conde-Garrosa R; Mañes S; Zelenay S; Melero I; Iborra S; Krummel MF; Sancho D
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33980589
[TBL] [Abstract][Full Text] [Related]
13. Blocking senescence and tolerogenic function of dendritic cells induced by γδ Treg cells enhances tumor-specific immunity for cancer immunotherapy.
Si F; Liu X; Tao Y; Zhang Y; Ma F; Hsueh EC; Puram SV; Peng G
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580332
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
[TBL] [Abstract][Full Text] [Related]
15. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
16. Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment.
Zhao Y; Shao Q; Peng G
Cell Mol Immunol; 2020 Jan; 17(1):27-35. PubMed ID: 31853000
[TBL] [Abstract][Full Text] [Related]
17. The immune-checkpoint HLA-G/ILT4 is involved in the regulation of VEGF expression in clear cell renal cell carcinoma.
García M; Palma MB; Verine J; Miriuka S; Inda AM; Errecalde AL; Desgrandchamps F; Carosella ED; Tronik-Le Roux D
BMC Cancer; 2020 Jul; 20(1):624. PubMed ID: 32620162
[TBL] [Abstract][Full Text] [Related]
18. TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy.
Molgora M; Esaulova E; Vermi W; Hou J; Chen Y; Luo J; Brioschi S; Bugatti M; Omodei AS; Ricci B; Fronick C; Panda SK; Takeuchi Y; Gubin MM; Faccio R; Cella M; Gilfillan S; Unanue ER; Artyomov MN; Schreiber RD; Colonna M
Cell; 2020 Aug; 182(4):886-900.e17. PubMed ID: 32783918
[TBL] [Abstract][Full Text] [Related]
19. To Remember or to Forget: The Role of Good and Bad Memories in Adoptive T Cell Therapy for Tumors.
Mondino A; Manzo T
Front Immunol; 2020; 11():1915. PubMed ID: 32973794
[TBL] [Abstract][Full Text] [Related]
20. Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation.
Zhou S; Meng F; Du S; Qian H; Ding N; Sha H; Zhu M; Yu X; Wang L; Liu B; Wei J
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
